BioSpace News Archive

Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma” or “the Company”) today announced that results from the multicenter, randomized, double-masked, vehicle-controlled Phase 3 clinical trial (The ONSET-2 study) of TYRVAYATM Nasal Spray (varenicline solution) have been published in Ophthalmology.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), today announced new data from a post-hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled NODE-301 trial of etripamil nasal spray, the Company’s novel investigational, short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).

Senhwa Biosciences, Inc. announced that an abstract highlighting clinical design for their lead drug candidate, Pidnarulex, in patients with solid tumors and BRCA2 and/or PALB2 mutation, has been accepted for trial in progress poster presentation at the upcoming American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, 20-22 January, 2022.

CollPlant Biotechnologies, a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the launch of Collink.3D, a recombinant human collagen - based BioInk solution for use in 3D bioprinting.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the last patient has been enrolled in Part A of the Phase 2/3 study with novel, once-daily, orally-administered pill RHB-107 (upamostat)[1] for non-hospitalized patients with symptomatic COVID-19.

CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that Mr. Larry Zhang, President of CASI Pharmaceuticals, will be presenting at the Jefferies London Healthcare Conference.

Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist” or “the Company”) today announced results from a Phase 2a study in which rusfertide, an investigational new drug, is being evaluated for the treatment of hereditary hemochromatosis (HH).

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone.

Repare Therapeutics Inc. today announced that members of its senior management team will participate in two virtual investor conferences in November.

PureTech Health plc today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences. Webcasts of the presentations will be available at https://investors.puretechhealth.com/events-presentations.